Clint Dart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women

/PRNewswire/ Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the.

Amy raskopfEvofem bioscienceClint dartEvofem biosciencesSaundra pelletierBrandi howardLisa rarickSecurities exchangeEvofem biosciences incPrnewswire evofem biosciences incChief executive officerSecurities exchange actPrivate securities litigation reform actAnnual reportQuarterly report

Evofem Biosciences (EVFM) Reports Phase 3 EVOGUARD Trial of EVO100 Did Not Achieve Endpoints

Evofem Biosciences (EVFM) Reports Phase 3 EVOGUARD Trial of EVO100 Did Not Achieve Endpoints
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Clint dartSaundra pelletierBrandi howardLisa rarickEvofem biosciences incChief executive officer

Seven Abstracts to be Presented on Evofem Biosciences Vaginal pH Modulator

Seven Abstracts to be Presented on Evofem Biosciences Vaginal pH Modulator
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesScott mollanAmy raskopfB todd chappellClint dartTeresa beckerEvofem biosciencesBrandon howardRonald surowitzKelly culwellBrandi howardTeresia leeJohn powersScientific congress expo in baltimoreAmerican society for reproductive medicineEvofem biosciences inc

Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting

Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 28, 2021 /PRNewswire/ Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two new data sets from its Phase 3 AMPOWER trial evaluating ® (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM). The meeting will be conducted virtually from April 30 - May 2, 2021. These new data sets provide clinical insights into how women used Phexxi in the AMPOWER clinical trial as well as their feelings about pregnancy, which are both important factors for clinicians to consider when counseling and prescribing Phexxi, said Brandi Howard, PhD, Head of Medical Affairs at Evofem Biosciences.

United statesClint dartPatty casonDavidj portmanDavidl eisenbergEvofem biosciencesEllen thomasBrandon howardEvofem bioscienceKelly culwellBrandi howardBassem maximosBiosciences incHead of medical affairs at evofem biosciencesAmerican college of obstetriciansSecurities exchange